Psoriasis is a T-cell-mediated illness that affects a large percentage of the population. Psoriasis is increasingly recognized as a multi-system inflammatory condition, rather than only a skin disease. In addition, the disease's chronicity has a major psychological impact on the patient's and cares quality of life. To arrest the so-called psoriatic march, proper illness management is crucial. Because there is no one-size-fits-all treatment for psoriasis, lifestyle changes, comorbidities, and the elimination of disease-modifying medicines must all be included in the treatment plan. There are a variety of treatments available for psoriasis, ranging from topical medicines to phototherapy to systemic therapy and biologics. The therapeutic module, particularly pharmaceutical selection, can be influenced by a variety of circumstances. The patient's age, risk factor, past therapeutic response, sickness severity and stability, and treatment cost are all aspects to consider. It is not uncommon to find difficult to treat psoriasis patients who have not responded, have not tolerated, or have exhausted all well-established therapeutic choices because to risk factors, side effects, or the high cost of the drugs. Psoriasis therapy has progressed rapidly over the years, and as a result, patients may now enjoy a great quality of life. This has occurred in concert with our improving understanding of the pathophysiology of the disease. It is deserving of recognition as a shining example of excellent research that demonstrates the importance of research to humanity's future. Directly tackling immunological pathways in order to treat psoriasis with innovative biologics and small molecules has led to the discovery that the most successful patient care approach is a holistic one that acknowledges the biopsychosocial aspect of the condition. Despite everything that has been said, there is still much more to learn, and more research is needed to enhance patient quality of life.